Abstract
Objective:
The objective of this article is to illustrate examples of radiologic immune-related response criteria and toxicity in patients with advanced melanoma treated with the immunotherapeutic agent ipilimumab.
Conclusion:
Novel immune-related tumor response criteria should be applied to patients undergoing therapy with ipilimumab for advanced melanoma. Ipilimumab also produces a spectrum of immune-related adverse effects that can be recognized radiologically.
MeSH terms
-
Antibodies, Monoclonal / adverse effects*
-
Drug-Related Side Effects and Adverse Reactions / diagnostic imaging*
-
Drug-Related Side Effects and Adverse Reactions / immunology
-
Humans
-
Immunotherapy / adverse effects*
-
Ipilimumab
-
Melanoma / drug therapy*
-
Melanoma / immunology
-
Melanoma / pathology
-
Neoplasm Staging
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / immunology
-
Skin Neoplasms / pathology
-
Tomography, X-Ray Computed*
Substances
-
Antibodies, Monoclonal
-
Ipilimumab